- Home
- GNLX vs APLT Comparison
GNLX vs APLT Comparison
Compare GNLX & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GNLX | APLT |
|---|---|---|
| Founded | 2001 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 202.4M | 38.1M |
| IPO Year | 2023 | 2019 |
Fundamental Metrics
Financial Performance| Metric | GNLX | APLT |
|---|---|---|
| Price | $4.17 | $0.12 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 3 |
| Target Price | ★ $19.75 | $1.25 |
| AVG Volume (30 Days) | 168.1K | ★ 9.3M |
| Earning Date | 11-05-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,000,000.00 |
| Revenue This Year | N/A | $124.18 |
| Revenue Next Year | N/A | $66.67 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.99 | $0.10 |
| 52 Week High | $8.54 | $1.50 |
Technical Indicators
Market Signals| Indicator | GNLX | APLT |
|---|---|---|
| Relative Strength Index (RSI) | 36.54 | 26.58 |
| Support Level | $4.00 | $0.10 |
| Resistance Level | $4.75 | $0.26 |
| Average True Range (ATR) | 0.37 | 0.02 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 14.71 | 15.57 |
Price Performance
Historical ComparisonAbout GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.